Gilead Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gilead Sciences sits in the top decile of US sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count).
Gilead Sciences: 504 sponsored US clinical trials, 26 recruiting.
Gilead Sciences sponsors 504 registered US clinical trials on ClinicalTrials.gov, 26 of them currently recruiting, and 346 completed. 164 of these trials are in Phase 3-4 (later-stage) and 317 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 20 trials.
Top-decile sponsor footprint
Gilead Sciences ranks in the top decile of sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
504 total, page 1 of 11
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
NCT07546812
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287
Study of GS-2426 in Participants With Advanced Solid Tumors
NCT07601243
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778
Study of GS-5319 in Adults With Solid Tumors
NCT07128303
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
NCT07055451
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
NCT07096193
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716
Study of GS-3242 in Participants With HIV-1; Substudy-05
NCT07001319
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
NCT06749054
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
NCT06532656
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06562907
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
NCT06532565
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
NCT06167317
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
NCT06613685
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960
Study of GS-0272 in Participants With Rheumatoid Arthritis
NCT06031415
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
NCT06060665
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
NCT05729568
Study of GS-4528 in Adults With Solid Tumors
NCT05840224
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
NCT05052996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 134 |
| Phase 2 | 183 |
| Phase 3 | 150 |
| Phase 4 | 14 |
What is open in the Gilead Sciences pipeline
26 recruiting of 504 indexed (5% open); 346 completed (69%).
Phase mix: 164 late (III/IV) vs 317 early (I/II) (early-phase heavy).
Top condition: HIV-1-infection (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gilead Sciences: open-pipeline peers nationwide
Peers matched on 504 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 504 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Creighton University · 5% recruiting · 98 trials
- Almirall, S.A. · 5% recruiting · 19 trials
- Cordis US · 5% recruiting · 19 trials
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
Related
What to do with this Gilead Sciences page
504 registered trials is a research-attention snapshot, not an endorsement of Gilead Sciences or any single study.
- 26 of Gilead Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV-1-infection is the condition Gilead Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gilead Sciences pipeline card: 504 registered trials from official public datasets.Report a data error.